← Eichor
Study identifier: NCT02455479 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Safety Study of a Disrupted Adenovirus (Ad) Serotype Cocaine Vaccine for Cocaine-dependent Individuals

Condition: Cocaine Dependence  ·  Sponsor: Weill Medical College of Cornell University

PhasePhase 1
Planned participants150
Who can joinAll sexes, 21 Years to 69 Years
Healthy volunteersNo

About this study

The purpose of this study is to assess the safety and preliminary efficacy of an anti-cocaine vaccine called dAd5GNE in cocaine-dependent individuals. It uses the concept of a vaccine to treat the neurological effects of cocaine by evoking "immunity" to prevent the effects of cocaine on the brain.

This description comes directly from the study's public registry record.

Talk to the study team

Sandra Hyde  ·  646-962-2672  ·  sah2003@med.cornell.edu

Always discuss trial participation with your own doctor first.

Locations (1)

WCMC Department of Genetic MedicineNew York, New York, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT02455479